Evaluation of the use of methylprednisolone and dexamethasone in asthma critically ill patients with COVID-19: a multicenter cohort study

[1]  Ohoud Aljuhani,et al.  Standard dosing of enoxaparin versus unfractionated heparin in critically ill patient with COVID-19: a multicenter propensity-score matched study , 2022, Thrombosis Journal.

[2]  Ohoud Aljuhani,et al.  Evaluation of inhaled nitric oxide (iNO) treatment for moderate-to-severe ARDS in critically ill patients with COVID-19: a multicenter cohort study , 2022, Critical Care.

[3]  G. Sandhu,et al.  Secondary Infection Risk in Patients With Severe COVID-19 Pneumonia Treated With Tocilizumab , 2022, American journal of therapeutics.

[4]  Lujun Qiao,et al.  The roles of methylprednisolone treatment in patients with COVID-19: A systematic review and meta-analysis , 2022, Steroids.

[5]  Brij Bhushan Mehta,et al.  Role of Dexamethasone and Methylprednisolone Corticosteroids in Coronavirus Disease 2019 Hospitalized Patients: A Review , 2022, Frontiers in Microbiology.

[6]  Ohoud Aljuhani,et al.  Statins and Risk of Thrombosis in Critically ill Patients with COVID-19: A Multicenter Cohort Study , 2022, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[7]  Ohoud Aljuhani,et al.  The Role of Inhaled Corticosteroids (ICS) in Critically Ill Patients With COVID-19: A Multicenter, Cohort Study , 2021, Journal of intensive care medicine.

[8]  Ohoud Aljuhani,et al.  Association between tocilizumab and emerging multidrug-resistant organisms in critically ill patients with COVID-19: A multicenter, retrospective cohort study , 2021, BMC Infectious Diseases.

[9]  Ohoud Aljuhani,et al.  Evaluation of zinc sulfate as an adjunctive therapy in COVID-19 critically ill patients: a two center propensity-score matched study , 2021, Critical Care.

[10]  Abdulmalik M. Alkatheri,et al.  Clinical features and outcomes of critically ill patients with coronavirus disease 2019 (COVID-19): A multicenter cohort study , 2021, International Journal of Infectious Diseases.

[11]  Wei Yang,et al.  A Comparison of Methylprednisolone and Dexamethasone in Intensive Care Patients With COVID-19 , 2021, medRxiv.

[12]  M. Moghadami,et al.  Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial , 2021, BMC Infectious Diseases.

[13]  J. Mallat,et al.  Effects of Methylprednisolone on Ventilator-Free Days in Mechanically Ventilated Patients with Acute Respiratory Distress Syndrome and COVID-19: A Retrospective Study , 2021, Journal of clinical medicine.

[14]  Animut Alebel,et al.  Effects of undernutrition on mortality and morbidity among adults living with HIV in sub-Saharan Africa: a systematic review and meta-analysis , 2021, BMC Infectious Diseases.

[15]  K. Khan,et al.  Comparison of efficacy of dexamethasone and methylprednisolone in moderate to severe covid 19 disease , 2020, Annals of Medicine and Surgery.

[16]  Q. Bassat,et al.  Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With COVID-19 (Metcovid): A Randomised, Double-Blind, Phase IIb, Placebo-Controlled Trial , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  J. van Paassen,et al.  Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes , 2020, Critical Care.

[18]  T. H. Nguyen,et al.  Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2020, The Lancet. Respiratory medicine.

[19]  Xin Li,et al.  COVID-19 with Different Severities: A Multicenter Study of Clinical Features , 2020, American journal of respiratory and critical care medicine.

[20]  Xin Zhou,et al.  Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China , 2020, The Journal of Emergency Medicine.

[21]  Zunyou Wu,et al.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.

[22]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[23]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[24]  P. Marik,et al.  Critical illness-related corticosteroid insufficiency (CIRCI): a narrative review from a Multispecialty Task Force of the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM) , 2017, Intensive Care Medicine.

[25]  Mamoru Sato.  ’Scape , 2017, Encyclopedia of Food and Agricultural Ethics.

[26]  S. Georas,et al.  Epithelial barrier function: at the front line of asthma immunology and allergic airway inflammation. , 2014, The Journal of allergy and clinical immunology.

[27]  A. Rebuck,et al.  PREDNISONE AND METHYLPREDNISOLONE DISPOSITION IN THE LUNG , 1983, The Lancet.

[28]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..